The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine
Open accessAbstract
A new polyvalent melanoma cell vaccine (MCV) was administered to 136 stage IIIA and IV (American Joint Committee on Cancer) melanoma patients. Induction of cell-mediated and humoral immune responses to common melanoma-associated antigens present on autologous melanoma cells was observed in patients receiving the new MCV. This was accompanied by increased activation of tumor-infiltrating lymphocytes. Survival correlated significantly with delayed cutaneous hypersensitivity (p = 0.0066) and antibody responses to MCV (p = 0.0117). Of 40 patients with evaluable disease, nine (23%) had regressions (three complete). From our historical database of 126 stage IIIA and 1275 stage IV melanoma patients, there were no significant changes in the natural history of metastatic melanoma during the past 20 years. Univariate and multivariate analyses demonstrated prognostic significance for site of metastases (p = 0.0001) and immunotherapy with the new MCV (p = 0.0001). Overall our new MCV increased the median and 5-year survival of stage IIIA melanoma patients with regional soft tissue metastases twofold (p = 0.00024), and stage IV patients threefold (p = 0.0001) compared with previous immunotherapy and other treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosenberg, S. A., Packard, B. S., Aebersold, P. M., Solomon, D., Topalian, S. L., Toy, S. T., Simon, P., Lotze, M. T., Yang, J. C., Seipp, C. A., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198812223192527 · Cited by 2,389
Experience with the Use of High-Dose Interleukin-2 in the Treatment of 652 Cancer Patients
ROSENBERG, S. A., LOTZE, M. T., YANG, J. C., AEBERSOLD, P. M., LINEHAN, W. M., SEIPP, C. A., & WHITE, D. E. (1989) · Annals of Surgery · doi:10.1097/00000658-198910000-00008 · Cited by 1,002
Treatment of Established Renal Cancer by Tumor Cells Engineered to Secrete Interleukin-4
Golumbek, P. T., Lazenby, A. J., Levitsky, H. I., Jaffee, L. M., Karasuyama, H., Baker, M., & Pardoll, D. M. (1991) · Science · doi:10.1126/science.1948050 · Cited by 719
Immunological factors which influence response to immunotherapy in malignant melanoma.
Morton, D. L., Eilber, F. R., Malmgren, R. A., & Wood, W. C. (1970) · PubMed · Cited by 461
Self-citationBCG lmmunotherapy of Malignant Melanoma: Summary of a Seven-year Experience
MORTON, D. L., EILBER, F. R., HOLMES, E. C., HUNT, J. S., KETCHAM, A. S., SILVERSTEIN, M. J., & SPARKS, F. C. (1974) · Annals of Surgery · doi:10.1097/00000658-197410000-00029 · Cited by 449
Self-citationDemonstration of antibodies against human malignant melanoma by immunofluorescence.
Dl, M., Malmgren, R. A., Ec, H., & Ketcham, A. S. (1968) · PubMed · Cited by 386
Berd, D., Maguire, H. C., Jr., & Mastrangelo, M. J. (1986) · PubMed · Cited by 251
Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2.
Cahan, L. D., Irie, R. F., Singh, R., Cassidenti, A., & Paulson, J. C. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.24.7629 · Cited by 242
Self-citationMitchell, M. S., Kan‐Mitchell, J., Kempf, R. A., Harel, W., Shau, H., & Lind, S. (1988) · PubMed · Cited by 236
Cheresh, D. A., Varki, A. P., Varki, N. M., Stallcup, W. B., Levine, J., & Reisfeld, R. A. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42812-2 · Cited by 222
Cited by
Cancer immunotherapy: moving beyond current vaccines
Rosenberg, S. A., Yang, J. C., & Restifo, N. P. (2004) · Nature Medicine · doi:10.1038/nm1100 · Cited by 2,972
Jemal, A., Clegg, L. X., Ward, E., Ries, L. A. G., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N., & Edwards, B. K. (2004) · Cancer · doi:10.1002/cncr.20288 · Cited by 1,140
Fawzy, F. I. (1993) · Archives of General Psychiatry · doi:10.1001/archpsyc.1993.01820210015002 · Cited by 1,028
Current state of melanoma diagnosis and treatment
Davis, L. E., Shalin, S. C., & Tackett, A. J. (2019) · Cancer Biology & Therapy · doi:10.1080/15384047.2019.1640032 · Cited by 922
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Metadata
- Authors
- MORTON, D. L., FOSHAG, L. J., HOON, D. S. B., NIZZE, J. A., WANEK, L. A., CHANG, C., DAVTYAN, D. G., GUPTA, R. K., ELASHOFF, R., & IRIE, R. F.
- Venue
- Annals of Surgery
- Published
- 1992-10
- Volume
- 216
- Issue
- 4
- Pages
- 463-482
- ISSN
- 0003-4932 (ISSN-L)
- OpenAlex
- W2081774451
- Cited by
- 403
- References
- 22
- FWCI
- 5.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine. https://app.cochat.ai/papers/10.1097/00000658-199210000-00010
- The paper
- MORTON, D. L., FOSHAG, L. J., HOON, D. S. B., NIZZE, J. A., WANEK, L. A., CHANG, C., DAVTYAN, D. G., GUPTA, R. K., ELASHOFF, R., & IRIE, R. F. (1992). Prolongation of Survival in Metastatic Melanoma After Active Specific Immunotherapy With a New Polyvalent Melanoma Vaccine. Annals of Surgery. https://doi.org/10.1097/00000658-199210000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.